16,16-Dimethyl Prostaglandin E2
(Synonyms: 16,16dimethyl PGE2) 目录号 : GC11133
derivative of prostaglandin E2
Cas No.:39746-25-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: N/A
16,16-Dimethyl Prostaglandin E2 (dmPGE2) is the synthetic derivative ofprostaglandin E2. Since prostaglandin E has immunosuppressive effects and potentially could lessen the toxic effects of cyclosporine, prostaglandin E usage in the setting of allotransplantation has been suggested both clinically and experimentally.
In vitro: DmPGE2 was reported to cause an increase in runx11/cmyb1 HSCs, while HSCs were inhibited by indomethacin treatment in 90% of embryos. Moreover, dmPGE2 had minimal effects on the vasculature, while indomethacin altered the intersomitic vessels slightly. Imaged by confocal microscopy, red-labelled HSCs and endothelium embryos showed significantly increased HSCs following dmPGE2 exposure [1].
In vivo: In a heterotopic model of rat allograft rejection, dmPGE2 could delay the rejection onset, but all animals developed severe rejection and died subsequently. Treatment of animals with low-dose CsA in combination with dmPGE2 led to a delay in the onset as well as a reduction in the intensity of allograft rejection. In addition, a statistical relationship between procoagulant activity levels and the time of onset of rejection was observed [1].
Clinical trial: N/A
References:
[1] North TE,Goessling W,Walkley CR,Lengerke C,Kopani KR,Lord AM,Weber GJ,Bowman TV,Jang IH,Grosser T,Fitzgerald GA,Daley GQ,Orkin SH,Zon LI. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature.2007 Jun 21;447(7147):1007-11.
[2] Koh IH,Kim PC,Chung SW,Waddell T,Wong PY,Gorczynski R,Levy GA,Cohen Z. The effects of 16, 16 dimethyl prostaglandin E2 therapy alone and in combination with low-dose cyclosporine on rat small intestinal transplantation. Transplantation.1992 Oct;54(4):592-8.
| Cas No. | 39746-25-3 | SDF | |
| 别名 | 16,16dimethyl PGE2 | ||
| 化学名 | (E)-7-((1R,2S,3R)-3-hydroxy-2-((R,E)-3-hydroxy-4,4-dimethyloct-1-en-1-yl)-5-oxocyclopentyl)hept-5-enoic acid | ||
| Canonical SMILES | O[C@H](C1)[C@@H](/C=C/[C@H](C(C)(C)CCCC)O)[C@@H](C/C=C/CCCC(O)=O)C1=O | ||
| 分子式 | C22H36O5 | 分子量 | 380.52 |
| 溶解度 | DMF: >100 mg/ml (from PGE2),DMSO: >100 mg/ml (from PGE2),Ethanol: >100 mg/ml (from PGE2),PBS pH 7.2: >5 mg/ml (from PGE2) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.628 mL | 13.1399 mL | 26.2798 mL |
| 5 mM | 0.5256 mL | 2.628 mL | 5.256 mL |
| 10 mM | 0.2628 mL | 1.314 mL | 2.628 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
-
Purity > 98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet